Zynerba Pharmaceuticals, Inc.
News
StockNews.com Begins Coverage on Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Ticker Report StockNews.com began coverage on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE Free Report) in a research report released on Friday. The firm issued a sell rating on the stock. Several other...\n more…
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
PR Newswire HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE PR Newswire...\n more…
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Receives New Coverage from Analysts at StockNews.com
Ticker Report StockNews.com began coverage on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE Free Report) in a report published on Thursday. The firm issued a sell rating on the stock. Several other...\n more…
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
Globe Newswire DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...\n more…
Bernardo Wealth Planning LLC Boosts Stock Position in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)
Ticker Report Bernardo Wealth Planning LLC grew its stake in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE Free Report) by 103.7% in the second quarter, according to its most recent disclosure with the...\n more…
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
Globe Newswire DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...\n more…